Clinical and endocrinological effects of letrozole during the luteal phase after controlled ovarian stimulation in oocyte donors: a low interventional, randomized, controlled trial
Phase 1
Recruiting
- Conditions
- Female InfertilityTherapeutic area: Phenomena and Processes [G] - Reproductive and Urinary Physiological Phenomena [G08]
- Registration Number
- CTIS2022-502586-21-00
- Lead Sponsor
- Ivi Madrid S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 152
Inclusion Criteria
Women who have been accepted into IVI's oocyte donation programme. - Age between 18 and 34 years, inclusive. - Hyperresponsiveness to stimulation, defined as the presence of =18 follicles of size =11 mm on the day of the last ultrasound control visit prior to ovarian puncture. - Dated and signed informed consent.
Exclusion Criteria
- Known allergy to letrozole. - Known lactose intolerance. - Participation in another clinical study, prior to inclusion in the present study, which could affect the objectives of the study in the opinion of the investigator.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method